Sign inJoin waitlistJoin the waitlist

Abdul Naqash

Director Immuno Oncology at Stephenson Cancer Center · University of Oklahoma College of Medicine

Credentials: · · · · · ·

History

University of Oklahoma College of Medicine
Present
University of Oklahoma College of Medicine
Present

Hematology and Medical Oncology
ECU Health Medical Center
2016–2019
National Cancer Institute
2012–2015
GOVT MED COLL, KASHMIR UNIV, SRINAGAR, JAMMU & KASHMIR, INDIA
2008–2012

Research

Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer
JAMA Oncology · 2020 · 397 citations
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
Journal of Oncology Pharmacy Practice · 2019 · 274 citations
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study
Hepatology · 2022 · 215 citations

Amin Nassar
28 papers · 2 as a fellow
AS
Anwaar Saeed
21 papers
Thomas Marron
21 papers
Biagio Ricciuti
20 papers · 13 as a resident
Mahvish Muzaffar
19 papers
Celina Ang
14 papers
Dwight Owen
14 papers
Paul Walker
14 papers
Yinghong Wang
14 papers
ES
Elad Sharon
13 papers
EA
Elio Adib
13 papers · 13 as a resident
Douglas Johnson
12 papers

Clinical trials

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population
Principal investigator · Active not recruiting
University of Oklahoma
2022–2027
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2, Phase 3
SWOG Cancer Research Network
2025–2028
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Site PI · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2023–2027
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2023–2028